PT97040A - Processo para a preparacao de derivados do acido glicolico - Google Patents

Processo para a preparacao de derivados do acido glicolico Download PDF

Info

Publication number
PT97040A
PT97040A PT97040A PT9704091A PT97040A PT 97040 A PT97040 A PT 97040A PT 97040 A PT97040 A PT 97040A PT 9704091 A PT9704091 A PT 9704091A PT 97040 A PT97040 A PT 97040A
Authority
PT
Portugal
Prior art keywords
alkyl
formula
compound
carbon atoms
treatment
Prior art date
Application number
PT97040A
Other languages
English (en)
Inventor
Peter Raddatz
Claus J Schmitges
Klaus-Otto Minck
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT97040A publication Critical patent/PT97040A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (3)

  1. substituído por A, AO e/ou Hal; cicloalquilalquilo oom 4 a 11 átomos de carbono; bicicloalquilo ou tri-cicloalquilo cada um com 7 a 14 átomos de carbono; bicicloalquilalquilo ou tricicloalquilalquilo cada um com 8 a 18 átomos de carbono; R^ significa (H, OH), (H,M2) ou = 0; R"^ significa Η, A ou OH; q ·) p i p n f,R K e 1 R significam também, cada um, um grupo pirro-lidino, piperidino, morfolino ou piperazino insubsti-tuído ou substituído por A, OH, m2, HHA, NAg, HHAc, Μ-ϋ0-0χΙί2χ-0-Η15, HH-OO- -O-C^H^-R15, bidroxialquilo, OOOII, COCA, COMHg, ami- noalquilo, HAH-alquilo, ÀgH-alquilo, A^H alquilo An ^ , M-CO-HHo, HH-QO-ΜΊΑ, guanidilo ou guanidil—alquilo; te R significa A ou Ar-alquilo; m, n e x significam, cada um, 0, 1, 2, 3, 4, 5, β, 7, S, 9 ou 10; Ar significa fenilo insubstituído ou monossubstituído ou polissubstituído por A, OA, ííal, Qly 0H> ií02» ^droxialqailo, HHg, HHA, NA2, HHAc, HH-SOg-A, SA, SO-A, SOg-A, SOgSHg, SOgHHA, COOII, COOA, OOHHg, 01, aminoalquilo, HAH-alquilo, AgH-alquilo, Ayl alquilo An® e/ou guanidinil-alquilo, ou naftilo insubstituído; Het significa um radical beterocíclico pentagonal ou bexa-gonal saturado ou insaturado, com 1 a 4 átomos de azoto, oxigénio e/ou enxofre, que pode ser condensado com um anel de benzeno e/ou ser monossubstituído ou polissubstituído por f ί
    A, OA, Hal, GI^, OH, carbonil-oxigénio, M2, HHA, NAg, MAc, 13H-000A, MCOOAr, HHOOOCHgAr, MH-SOg-A, SA, SO-A, SOg-A, SOgHHg, SOgHHA, COOH, GCOA, OOHHg, GiJ, Ar, Àr-alquilo, Ar-alcenilo, Hidroxialquilo, aminoalquilo, HA1T--alquilo, AgH-alquilo e/οα A^N alquilo, An® e/ou cujos heteroátomos de azoto e/ou enxofre podem também ser oxidados; Ilal significa fláor, cloro, bromo ou iodo; Ac significa A-CQ, Ar-CO-, Ar-alquil-CO ou A-iíH-CO; An® significa um anião que também pode ser omitido, se em vez dele, no composto de fórmula geral I, existir um grupo carboxi na forma de anião de car-boxilato; -alquil- significa um grupo alquileno com 1 a 8 átomos de carbono; e A significa alquilo com 1 a 8 átomos de carbono; em que, além disso, em vez de um ou vários grupos -NH-C0-, podem também estar presentes um ou vários grupos -HA-CC, assim como dos seus sais, caracterizado pelo facto de se libertar o composto de fórmula geral I a partir de um seu derivado funcional por tratamento com um agente de solvólise ou de Mdrogenólise ou se fazer reagir um ácido carboxílico de fórmula geral II X „1 Gx OH (II) na qual a) é omitido e1
    ou significa b) -Ο-ΟρΑρΛ-ΟΟ- 'ou c) -o-crAA-co-y- ou am dos seus derivados reactivos, com um composto de fdrmula geral III H- G 2- HR3- CHR4- CR5- 0II2- CR6 R7- Z (III) na qual G2 significa a) - O- CrAi2- 0 O- Y- ou b) -Y- ou c) é omitido e, eventualmente, num composto de fórmula geral (I) assim obti do se libertar um grupo amino e/ou um grupo hidroxi funcionalmente modificado por tratamento com agentes de solvólise ou de hidrogenólise e/ou se acilar um grupo amino livre por tratamento com um agente de acilação e/ou para a preparação de um composto de fórmula geral (I) em que R^ = (H, OH) ou (H, íííí2), se reduzir um derivado ou se aminar em condições redutoras um derivado de aminoceto-ácido de fórmula I em que R^ = 0 e/ou se transformar um compos do de fórmula I num seu sal por tratamento com um ácido.
  2. 2§. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de, como produto final, se obter um dos seguintes compostos de fórmula geral I: a) amida do ácido H-(2-isopropil-4-b.idroxi-5-(4-aminopiperi-dinocarb onil-Pla-His-amino)-6-ciclo-hexil-liexil)-propa-nossulfónico; b) H-et il- J' -/!- hidroxi- 5- (4-aminopiperidinocarbonil-Pla-TIis· * ' r i
    -amino7-6- ciclo-hexil-hexil7- ureia; c) H-etil-iT'-/?-liidroxi-5- (4-aminopiperidinocarbonil-Pla- - (S-Ke-Oys)- amino) - 5-ciclo-hexil-hexil7- ureia.
  3. 3§. - Processo para a preparação de composições farmacêuticas, caraeterizado pelo facto de se misturar pelo menos um derivado do ácido glicolico de formula geral I e/ou um seu sal de adição de ácido fisiologioamente aceitável com uma substância veicular ou auxiliar sólida, líquida ou semilíquida farmaceu-ticamente aceitável e se conferir à referida mistura a forma de dosagem unitária apropriada. 42-. - Processo para 0 tratamento de seres humanos e/ou animais que sofrem de perturbações provocadas por excesso de renina em circulação, caraeterizado pelo facto de se administrar aos referidos pacientes uma dose diária dum derivado de ácido gli-cólico de fórmula geral I ou dum seu sal farmaceuticamente aceitável, de acordo com a reivindicação 1, de preferência, compreendida entre cerca de 0,2 e 20 mg de substância activa por quilograma de peso corporal. líSboa, K :¾ ,yc,j 0 Agente Oficial da Propriedade Industrial
    Américo da Silva Carvaiho Agonie Oficial da Propriedade Industrial R. Castilho, 201-3. H.-1000 LiSBOA Telefs. 65 13 39-65 46 13
PT97040A 1990-03-16 1991-03-14 Processo para a preparacao de derivados do acido glicolico PT97040A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4008403A DE4008403A1 (de) 1990-03-16 1990-03-16 Glykolsaeurederivate

Publications (1)

Publication Number Publication Date
PT97040A true PT97040A (pt) 1991-10-31

Family

ID=6402336

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97040A PT97040A (pt) 1990-03-16 1991-03-14 Processo para a preparacao de derivados do acido glicolico

Country Status (11)

Country Link
US (1) US5147857A (pt)
EP (1) EP0446751A1 (pt)
JP (1) JPH0532609A (pt)
KR (1) KR910016739A (pt)
AU (1) AU650442B2 (pt)
CA (1) CA2038282A1 (pt)
DE (1) DE4008403A1 (pt)
HU (1) HU207508B (pt)
IE (1) IE910890A1 (pt)
PT (1) PT97040A (pt)
ZA (1) ZA911951B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506268A (en) * 1993-06-11 1996-04-09 Nps Pharmaceuticals, Inc. Use of isovaleramide as a mild anxiolytic and sedative agent
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
US9777551B2 (en) 2011-08-22 2017-10-03 Downhole Technology, Llc Downhole system for isolating sections of a wellbore
US8955605B2 (en) 2011-08-22 2015-02-17 National Boss Hog Energy Services, Llc Downhole tool and method of use
US10246967B2 (en) 2011-08-22 2019-04-02 Downhole Technology, Llc Downhole system for use in a wellbore and method for the same
US9896899B2 (en) 2013-08-12 2018-02-20 Downhole Technology, Llc Downhole tool with rounded mandrel
US10036221B2 (en) 2011-08-22 2018-07-31 Downhole Technology, Llc Downhole tool and method of use
US10570694B2 (en) 2011-08-22 2020-02-25 The Wellboss Company, Llc Downhole tool and method of use
US10316617B2 (en) 2011-08-22 2019-06-11 Downhole Technology, Llc Downhole tool and system, and method of use
CA2982989C (en) 2015-04-17 2020-01-14 Downhole Technology, Llc Downhole tool and system, and method of use
WO2018009487A1 (en) 2016-07-05 2018-01-11 Downhole Technology, Llc Downhole tool and method of use
WO2018094257A1 (en) 2016-11-17 2018-05-24 Downhole Technology, Llc Downhole tool and method of use
CA3081865C (en) 2018-04-12 2023-02-28 The Wellboss Company, Llc Downhole tool with bottom composite slip
WO2019209615A1 (en) 2018-04-23 2019-10-31 Downhole Technology, Llc Downhole tool with tethered ball
WO2020056185A1 (en) 2018-09-12 2020-03-19 The Wellboss Company, Llc Setting tool assembly
US11634965B2 (en) 2019-10-16 2023-04-25 The Wellboss Company, Llc Downhole tool and method of use
US11713645B2 (en) 2019-10-16 2023-08-01 The Wellboss Company, Llc Downhole setting system for use in a wellbore

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
US4880781A (en) * 1984-08-06 1989-11-14 The Upjohn Company Renin inhibitory peptides containing an N-alkyl-histidine moiety
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
EP0249096B1 (de) * 1986-06-10 1995-01-11 Merck Patent Gmbh Reninhemmende Aminosäurederivate.
JPS6322081A (ja) * 1986-07-11 1988-01-29 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
ES2053582T3 (es) * 1986-08-13 1994-08-01 Ciba Geigy Ag Procedimiento para la obtencion de derivados del acido 5-amino-4-hidroxivalerianico.
HU204285B (en) * 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
US4804743A (en) * 1987-01-29 1989-02-14 Warner-Lambert Copmany Proline-containing renin inhibitors
GB8707412D0 (en) * 1987-03-27 1987-04-29 Fujisawa Pharmaceutical Co Peptide compounds
US4921855A (en) * 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
DE3822841A1 (de) * 1988-06-18 1989-12-21 Hoechst Ag Substituierte sulfonyldiamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide und pflanzenwachstumsregulatoren
US4986845A (en) * 1988-07-15 1991-01-22 Nissan Chemical Industries Ltd. Pyrazole derivatives and herbicides containing them
FR2642422A1 (fr) * 1988-12-22 1990-08-03 Roussel Uclaf Nouvelles polyamines acylees, leur procede de preparation et leur application comme fongicides
DK0417698T3 (da) * 1989-09-12 1996-07-22 Hoechst Ag Aminosyrederivater med reninhæmmende egenskaber, fremgangsmåde til deres fremstilling, midler med indhold deraf og deres anvendelse
DE4106488A1 (de) * 1991-03-01 1992-09-03 Merck Patent Gmbh Peptid-analoga

Also Published As

Publication number Publication date
ZA911951B (en) 1991-12-24
JPH0532609A (ja) 1993-02-09
AU7290691A (en) 1991-09-19
KR910016739A (ko) 1991-11-05
HUT59939A (en) 1992-07-28
HU207508B (en) 1993-04-28
DE4008403A1 (de) 1991-09-19
AU650442B2 (en) 1994-06-23
IE910890A1 (en) 1991-09-25
HU910846D0 (en) 1991-09-30
EP0446751A1 (de) 1991-09-18
US5147857A (en) 1992-09-15
CA2038282A1 (en) 1991-09-17

Similar Documents

Publication Publication Date Title
PT97040A (pt) Processo para a preparacao de derivados do acido glicolico
GB2239797B (en) Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combatting retroviruses
US20080194683A1 (en) Medicament for preventing and/or treating peripheral neuropathies
US5547964A (en) Medical use for tachykinin antagonists
EP0693285A2 (en) Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss
US5175006A (en) Method of treating arthritis using gallium compounds
US6200607B1 (en) Pharmaceutical composition comprising at least tyrosine and an iron compound for treating parkinson's disease or depression
BG63821B1 (bg) Фармацевтичен състав на стабилизиран карбапенемовантибиотик и метод за получаване
DE68908145T2 (de) Verwendung von L-Carnitinderivaten zur Herstellung eines Arzneimittels zur therapeutischen Behandlung von peripheren Neuropathien.
EP0688215A1 (en) 3,4-diarylchromans for treatment of dermatitis
SK7795A3 (en) Bioactive compositions, preparation and use thereof
MY108482A (en) Compounds.
GB9109972D0 (en) Therapeutic compounds
EP0413583A2 (en) Clear, stable cromolyn formulation
CA1248454A (en) Cytidyl diphosphocholine-drug composition and process
AU2003283807A1 (en) Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
US5846977A (en) Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration
EP0362587A2 (en) Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
EP1420782B1 (en) Use of nefiracetam for treating post-stroke neurodegeneration
PT97100A (pt) Processo para a preparacao de derivados de indol
EP0797997B1 (de) Verwendung von peptidischen Bradykinin-Antagonisten zur Herstellung von Arzneimitteln
EP0082546B2 (en) Pharmaceutical mixture and method for making the mixture
US5641781A (en) Topical ophthalmic composition comprising a 2-[4-(azolylbutyl)piperazinylmethyl]benzimidazole derivative, in particular for the treatment of allergic conjunctivitis
US4866082A (en) Inhibition of bone loss by (-)-N-[[(5-chloro-2-benzothiazolyl)thio]phenylacetyl]-L-cysteine
EP0504483B1 (en) Rectal compositions containing lyophilized calcitonin

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910710

FC3A Refusal

Effective date: 19971014